InvestorsObserver is giving BELLUS Health Inc (BLU) an Analyst Rating Rank of 70, meaning BLU is ranked higher by analysts than 70% of stocks. The average projection by analysts for BLU is $8.2 over the next 12 months and analyst’s classify the stock as a Strong Buy
Why are Analyst Ratings Important?
Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.
InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.
What's Happening With BELLUS Health Inc Stock Today?
BELLUS Health Inc (BLU) stock has fallen -4.14% while the S&P 500 has risen 0.57% as of 10:36 AM on Tuesday, Dec 15. BLU has fallen -$0.13 from the previous closing price of $3.14 on volume of 535,499 shares. Over the past year the S&P 500 has risen 14.94% while BLU has fallen -57.55%. BLU lost -$0.60 per share the over the last 12 months.